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andomized Clinical Trials and
bservational Studies
uidelines for Assessing Respective Strengths and Limitations
dward L. Hannan, PHD, MS, MS, FACC
ensselaer, New York
he 2 primary types of studies that are used to test new drugs or procedures or compare competing
rugs or types of procedures are randomized clinical trials (RCTs) and observational studies (OS). Al-
hough it would appear that RCTs always trump OS because they eliminate selection bias, there are
any possible limitations to both types of studies, and these limitations must be carefully assessed
hen comparing the results of RCTs and OS. This state-of-the art review describes these limitations
nd discusses how to assess the validity of RCTs and OS that yield different conclusions regarding the
elative merit of competing treatments/interventions. (J Am Coll Cardiol Intv 2008;1:211–7) © 2008 by
he American College of Cardiology FoundationA
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nhe 2 primary means by which alternative medical
r surgical treatments are assessed is through the
se of randomized controlled trials (RCTs) or
bservational studies (OS). The RCTs were first
ntroduced when streptomycin was evaluated as a
reatment for tuberculosis (1,2). In RCTs, partic-
pants are randomly assigned to a treatment or
ontrol group (or to multiple treatment groups) so
s to reduce bias by making the groups as equal as
ossible with respect to all patient characteristics
hat may have an impact on outcomes. Thus, in
heory, the only difference between the groups is
he treatment assignment and any differences that
re identified. In contrast, OS do not randomize
reatment but “observe” differences in outcomes
hat occur after treatment decisions have been
ade without regard to ensuring that patients in
ifferent treatment arms have similar characteris-
ics related to outcomes.
Evidence-based medicine classifies different
ypes of studies on the basis of research design as
he criterion for hierarchical rankings (2–4). Table
presents the American College of Cardiology/
rom the University at Albany School of Public Health, Rensselaer, New
ork.m
anuscript received October 24, 2007; revised manuscript received
ecember 17, 2007, accepted January 10, 2008.merican Heart Association (ACC/AHA) levels
f evidence for treatment recommendations (4). As
oted in the table, the highest level of evidence
Level A) is accorded to studies with “data derived
rom multiple randomized clinical trials or meta-
nalyses” and the second highest level (Level B) is
ssigned to studies with “data derived from a single
andomized trial, or non-randomized studies” (4).
It is assumed that a study design at a higher level
n the hierarchy is methodologically superior to one
t a lower level and that studies at the same level
re equivalent, but this ranking system is far too
implistic given the many design characteristics
hat comprise a given study.
Other hierarchies that are more comprehensive
han the American College of Cardiology/
merican Heart Association Levels of Evidence
nclude phrases such as “properly randomized,
ontrolled trial” (5), “well-designed controlled tri-
ls without randomization” (5), and “RCTs with
mportant limitations (inconsistent results, meth-
dological flaws, indirect or imprecise)” (6). How-
ver, even in these more detailed hierarchies, it is
ot clear how to revise the hierarchy if a trial is not
properly randomized” or “well designed.” Also,
he randomization and the quality of the design are
ot necessarily best described in a dichotomous
anner; rather there are many factors to consider
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212n designing a study, and it would appear that the bound-
ries of any hierarchy may be blurred by the quality of a
tudy’s design.
The purpose of this communication is to explore the pros
nd cons of RCTs and OS in general, but more importantly
o propose some criteria for evaluating the quality of RCTs
nd OS that will provide some insight regarding which
ption is appropriate for a given problem, and how to assess
he validity of RCTs and OS that yield different conclusions
egarding the relative merit of competing treatments/
nterventions.
omparing Evidence from RCTs and OS
irst, it is informative to review the results of some relatively
ecent studies that have used up-to-date meta-analytic
techniques to combine the out-
comes of similar OS and similar
RCTs that have studied the
same problem. Benson and
Hartz (7) examined OS pub-
lished between 1985 and 1998
that were aimed at comparing 2
or more treatments or interven-
tions for the same condition.
The Abridged Index Medicus
and Cochrane databases were
used to find all RCTs and OS
that compared the same treat-
ments for those conditions. Ben-
son and Hartz identified a total
of 136 different reports on 19
diverse treatments, including 7
cardiologic treatments: nifedi-
pine versus control in patients
with coronary artery disease;
coronary artery bypass graft
(CABG) surgery versus percuta-
eous transluminal coronary angioplasty (PTCA) in dia-
etic patients; CABG surgery versus PTCA in patients at
igh risk; CABG surgery versus PTCA in patients at low
isk; CABG surgery versus medical treatment in the CASS
Coronary Artery Surgery Study) trial; CABG surgery
ersus medical treatment in Duke study patients; and the
se of beta-blockers versus placebo (7). Their conclusions
ere that in only 2 of the 19 treatments did the combined
agnitude of the effect in the OS lie outside the 95%
onfidence interval (CI) for the combined magnitude of the
ffect in the RCTs. One of the 2 discrepant areas was in a
ardiologic treatment: the comparison of CABG and
TCA for patients at low risk (7). Benson and Hartz
oncluded that “we find little evidence that estimates of
bbreviations
nd Acronyms
MS  bare-metal stent(s)
ABG  coronary artery
ypass graft
I  confidence interval
ES  drug-eluting stent(s)
RT  hormone replacement
herapy
R  odds ratio
S  observational
tudy/studies
ES  paclitaxel-eluting
tent(s)
TCA  percutaneous
ranslumincal coronary
ngioplasty
CT  randomized
ontrolled trial(s)
R  relative riskreatment effects in OS reported after 1984 are either •onsistently larger than or qualitatively different than those
btained in randomized, controlled trials” (7).
Concato et al. (2) conducted a search for meta-analyses
hat compared outcomes of RCTs and OS. Five major
edical journals were searched from 1991 to 1995, and
ummary estimates and confidence intervals were computed
rom a total of 99 reports across 5 topic areas. These areas
ncluded the treatment of hypertension and stroke, the
reatment of hypertension and coronary heart disease, and
holesterol level and death due to trauma. The 2 other areas
ere breast cancer and tuberculosis.
They concluded that the mean results from the OS were
emarkably similar to the results from the RCTs. For
xample, for treatment of hypertension and stroke, the
ummary estimates were relative risk (RR) 0.58 (95% CI
.50 to 0.67) for RCTs and odds ratio (OR) 0.62 (95% CI
.60 to 0.65) for OS. For treatment of hypertension and
oronary heart disease they were RR 0.86 (95% CI 0.78 to
.96) and OR 0.77 (95% CI 0.75 to 0.80), respectively.
oncato et al. (2) concluded that the “results of well-
esigned studies. . .do not systematically overestimate the
agnitude of the effects of treatment as compared with
hose in randomized, controlled trials on the same topic.”
A recent study by Ioannidis et al. (8) compared the results
f evaluations of 45 medical treatments based on 240
andomized trials and 168 nonrandomized studies to judge
he consistency of results between the 2 types of studies.
hey found that there was very good correlation between
he summary odds ratios (R 0.75, p 0.001), but that the
onrandomized studies were more likely to show larger
reatment effects (28 vs. 11, p  0.009). They also found
hat there was frequent heterogeneity among study results
mong randomized studies and among nonrandomized
tudies (8).
omplementarity of RCTs and OS
hus, for the most part, RCTs and OS do arrive at the same
onclusions. Furthermore, RCTs and OS can be used
ynergistically to obtain more and better information about
he relative merits of alternative interventions/treatments.
or example, OS can be used to:
Test the external validity of RCTs by expanding the
settings to a more representative population (9);
Table 1. American College of Cardiology/American Heart Association
Levels of Evidence for Research Studies
Level of Evidence: A Data derived from multiple randomized clinical
trials or meta-analyses
Level of Evidence: B Data derived from a single randomized trial, or
unrandomized studies
Level of Evidence: C Consensus opinion of experts, case studies, or
standard of careFormulate hypotheses for RCTs to test (9);
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213Identify structures, processes, and outcomes to study
(10);
Help establish the appropriate sample size for an RCT
(10); and
Examine patient subsets to determine precisely which
patients benefit from each alternative intervention
easons Why RCTs and OS May Arrive at
ifferent Conclusions
owever, it is not always true that RCTs and OS arrive at
he same conclusions and, consequently, it is important to
sk what should be done when they do not agree. First, as
oted in Table 1, the ACC/AHA require multiple RCTs or
meta-analysis for their highest level of evidence and
ultiple OS (or 1 RCT) for their second-highest level.
hus, if 1 RCT differs from multiple OS, then there is a
ressing need to examine the studies more closely. The
ections to follow list reasons why the 2 types of studies may
rrive at different conclusions and of potential threats to
alidity of observational databases and RCTs.
election bias. Perhaps the most serious shortcoming of OS
s selection bias, whereby because of the absence of random-
zation, there may be large observed and unobserved differ-
nces in patient characteristics between the treatment and
ontrol (or between 2 or more treatment) groups (10).
hese differences can lead to biased estimates of the
reatment effects when one or more of the patient charac-
eristics for which there are differences are related to the
utcomes being measured (10). These factors are referred to
s confounders. RCTs were developed for the purpose of
liminating this bias.
As an example of this problem, a meta-analysis of all 25
S published through 1997 found that the RRs for coro-
ary heart disease for patients who ever used hormone
eplacement therapy (HRT) relative to patients who never
sed it were 0.70 (95% CI 0.65 to 0.75) for estrogen only
nd 0.66 (95% CI 0.53 to 0.84) for the combination of
strogen and progestin (11). However, in 2002, the Wom-
n’s Health Initiative study, an RCT with 16,000 post-
enopausal women that was planned for an 8-year follow-
p, was stopped because of an increase in the risk of breast
ancer and heart disease in women treated with HRT. This
nding led to recommendations that “. . .post-menopausal
omen who are considering estrogen or estrogen with
rogestin treatments should discuss with their health care
roviders whether the benefits outweigh the risks” (12). It is
ypothesized that the reason for this discrepancy was a
election bias in the OS, whereby women taking HRT were
ore likely to be in higher socioeconomic groups who have
ad better access to preventive health care their entire life
nd were therefore less likely to experience adverse health
utcomes (12). aThere are several ways in which selection bias related to
nown factors can be controlled for and reduced, although
ot entirely eliminated, including risk adjustment through
egression or analysis of variance methods (13–15), propen-
ity analysis (13,16,17), and instrumental variables (13,18).
Risk-adjustment generally involves the development of a
tatistical model (when the outcome is binary, usually either
logistic regression model for short-term outcomes or a
roportional hazards model for longer term outcomes) with
he outcome as a dependent variable. The type of treatment
s used as an independent variable along with the control
ariables, which are typically patient risk factors suspected or
nown to be related to adverse outcomes. Then the impact
f treatment type (OR for short-term outcomes or hazard
atio for longer-term outcomes) is a byproduct of the
tatistical model that measures the impact of treatment after
djusting for the control variables.
Propensity analysis is a method developed to match
atients in an observational study as well as possible with
egard to characteristics that are associated with the choice
f treatment. Typically, this is done by developing a logistic
egression model that has choice of treatment as a binary
ependent variable and the characteristics that are poten-
ially associated with treatment choice as the independent
ariables. Then, the probability of one of the treatments (say
reatment A) being chosen can be calculated from the
odel as a function of the characteristics, and pairs of
atients receiving each treatment and having identical or
imilar probabilities of Treatment A being chosen can be
dentified. Another way of controlling for propensity to
eceive one of the treatments is to use the propensity score
s an additional independent variable in the risk-adjustment
odel in addition to the patient characteristics. However, if
he variables used to predict the propensity score are
dentical or nearly identical to the other variables in the
odel, this variation of the method is not effective.
Instrumental variables are another method for controlling
or selection bias that require the use of a variable that is
elated to treatment choice but not to outcomes. This
pproach is not as popular as propensity analysis, at least in
art because it is sometimes difficult to identify an instru-
ental variable.
Perhaps the greatest threat to selection bias is related to
nobserved differences in patient characteristics, i.e., patient
haracteristics that are not contained in the observational
atabase (particularly data collected for clinical purposes).
hese characteristics cannot be controlled for nor can their
mpact be measured using the methods described previously.
herefore, if unobserved characteristics are significant pre-
ictors of outcome and if they are unbalanced with respect
o alternative treatments, then the potential for significant
ias exists in OS.
The presence of unobserved differences in patient char-cteristics should be minimized if possible by designing
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214bservational databases so as to include as many patient
haracteristics that are thought to impact outcomes as
ossible. Also, if there are patient characteristics that are
ssociated with contraindication of one of the treatments
eing considered, these contraindications should be in-
luded in the database if possible. For example, if drug-
luting stents (DES) are being compared with bare-metal
tents (BMS) in a time period in which DES are unavailable
n longer lengths, then either the lesion length could be
ncluded in the database or the fact that DES was contra-
ndicated because of the lesion length could be included as
data element. Thus, either lesion length could be con-
rolled for or patients with long lesions could be excluded
rom the analyses.
The danger of selection bias is exacerbated when the
bservational database is an administrative database rather
han a clinical database. An administrative database is a
atabase that is developed for purposes of reimbursement or
lanning as opposed to being created to compare treat-
ents/interventions or to evaluate quality of care. The
ajor drawbacks of administrative databases in evaluating
uality/comparing risk-adjusted outcomes for interventions
re the limited ability to distinguish between complications
f care (adverse outcomes) and pre-existing conditions (risk
actors in the risk-adjustment process), inability to specify
linical definitions for risk factors (e.g., forced reliance on
nternational Classification of Diseases-9 codes), and limi-
ations on the number of risk factors that are coded for each
atient (19–24). Despite these limitations, administrative
atabases do have great potential for evaluating care, par-
icularly if a limited number of clinical data elements can be
dded to them (19,23). Another advantage of administrative
atabases is that because they were not created for a
riori-defined research purposes, there is no opportunity for
nterviewer bias or ascertainment bias.
The presence of an important selection bias constitutes
ow internal validity of a study (ability of inferences from the
tudy to represent cause-effect relationships). Well-done
CTs are superior to OS because they eliminate selection
ias. However, there are many lower quality RCTs that
uffer from deficits in external validity (the extent to which
he results can be generalized beyond the sample). The
ollowing are some potential problems that relate to external
alidity.
eneralizability. One reason why an RCT and an observa-
ional study on the same competing interventions may arrive
t different conclusions is that they frequently apply to
ifferent patients. Randomized controlled trials have specific
nclusion and exclusion criteria that are often quite restric-
ive, whereas OS usually apply to a much broader popula-
ion and are frequently even population-based. There is
vidence that RCT populations usually don’t mirror the age,
ender, and race distribution of the target patient popula-
ion (25–29). In general, they tend to be less sick, younger, oetter educated, and of higher socioeconomic status. This
lso means that in RCTs, patients are more likely to be
dherent. This may tend to overstate the effect of a new
reatment had it been introduced in the entire target
opulation. In the case of RCTs that involve procedure-
ased interventions, informed consent can be more difficult
o obtain than it is in drug trials. As an example, it has been
stimated that as few as 2% to 5% of the patients screened
ere randomized in the early PTCA versus CABG trials
10). Thus, extrapolation to the entire population may be
nwise. Consequently, there is a possibility that if the OS
ad been restricted to the same set of exclusions and
nclusions as the RCT, its results may have been much more
imilar. On the other hand, the results for all patients in the
bservational study are of great interest because they reflect
ctual practice patterns and because they enable researchers
o conduct subset analyses that will speak to precisely which
atients benefit from each treatment/intervention.
Another threat to the generalizability of an RCT is that the
linicians or providers in the study are not representative of the
opulation of clinicians or hospitals who would ultimately be
sing the procedure/treatment. As an example, off-pump
ABG surgery is more demanding than traditional on-pump
urgery and it is likely that outcomes are more variable as a
unction of the skill or experience of the surgeon performing
he surgery. If an RCT comparing off-pump and on-pump
urgery is conducted by a group of surgeons with unusual
kill/experience in off-pump procedures, the conclusion of the
CT that off-pump surgery is superior to on-pump surgery
ay not translate to the general population of CABG surgery
atients. For example, van Dijk et al. (30) found 5-year
ortality rates of 8.5% for off-pump patients and 6.5% for
n-pump patients in a RCT performed in the Netherlands,
hereas Hannan et al. (31) found 3-year rates of 10.6% for
ff-pump and 9.9% for on-pump patients in a population-
ased study in New York. Reasons for the greater rates in New
ork may include lower-risk patients in the RCT, but also the
act that surgeons in the RCT had already traversed the longer
earning curve required for the demands of off-pump surgery.
nadequate statistical power. Because of the cost of RCTs,
he amount of time it takes to conduct them, the difficulty
ecruiting subjects, and the fact that because they generally
xpect only small to modest differences in outcomes (oth-
rwise they would be unethical), they are frequently under-
owered to detect important differences in outcomes. This
an lead to erroneous conclusions, generally false negatives,
.e., that there are no significant differences in treatments
hen a larger sample size would have uncovered significant
ifferences.
To achieve adequate statistical power, researchers can,
nd usually do conduct power analyses to determine the
ample size necessary to identify meaningful clinical differ-
nces between treatments. However, because of cost and
ther considerations, compromises are frequently made.
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215lso, power analyses are predicated on assumptions about
dverse outcome rates, which may prove to be inaccurate.
ne of the ways that RCTs attempt to combat the lack of
ufficient statistical power is to use combined outcomes
e.g., major adverse cardiac events rather than mortality) to
nhance the adverse outcome rate to compensate for inad-
quate sample size. However, a major drawback of this
ubstitution is that outcomes with far different levels of
everity are combined, and the results are frequently driven
y less important, and sometimes even subjective, outcomes
ith greater incidence rates.
For example, Freemantle et al. (32) report that in a system-
tic review of the use of composite end points that included
ortality in clinical trials published in 9 top medical journals
etween 1997 and 2001, among the 79 trials in which the
omposite end point yielded a statistically significant result, the
ortality end point by itself was only significant in 19 trials
24%). Freemantle et al. (32) concluded that “. . .reporting of
omposite outcomes is generally inadequate, implying that the
esults apply to the individual components of the composite
utcome rather than only to the overall composite.” In an
ccompanying editorial, Lauer and Topol (33) concluded that
when composite end points are used, the individual compo-
ents must be appropriately chosen, objectively measured in an
nbiased manner, and individually reported.”
Although this is excellent advice to follow, there remains
he danger that important components such as mortality are
eported separately and found to be nonsignificant, but
eemingly only because of inadequate statistical power. As
n example, in the PASSION (Paclitaxel-eluting Stent vs.
onventional Stent in Myocardial Infarction with ST-
egment Elevation) trial, which compared outcomes for
atients with ST-segment elevation myocardial infarction
ho were treated with BMS and paclitaxel-eluting stents
PES), Laarman et al. (34) assigned 619 ST-segment
levation myocardial infarction patients to PES and BMS.
he primary end point of the study was a composite of
eath from cardiac causes, recurrent myocardial infarction,
r target lesion revascularization at 1 year. Findings were
hat there was no significance in the rates of serious adverse
vents (8.8% vs. 12.8% in favor of PES, adjusted RR 0.63,
5% CI 0.37 to 1.07, p  0.092) (34). Nevertheless, it
ppears that the magnitude of these differences is clinically
mportant. In fact, with roughly 600 patients in each group,
he statistical power to detect a difference between 8.8% and
2.8% is only 72%. This power increases to a respectable
9% if the samples are of size 1,000 instead of 600.
In conclusion, combined end points and low statistical
ower can lead to misleading conclusions, but these prob-
ems can be overcome if there are sufficient resources
vailable to obtain adequate sample sizes. However, in my
iew many RCTs have not had adequate sample sizes for
esting what should have been the primary end point. sollow-up and approach to treating patients. Because RCTs
enerally have strictly defined follow-up criteria whereas
ollow-ups in OS are driven by variable physician-scheduled
ppointments and decisions of patients to seek care based on
ymptoms, different informationmay be available in the 2 types
f studies. These differences can lead to biases in each study.
or example, the absence of follow-ups in OS may result in
ncaptured complications that resulted in outpatient visits that
re not contained in the observational database.
However, it is also possible that mandated follow-ups in
CTs may bias outcomes in favor of one of the treatments.
or instance, in the COURAGE (Clinical Outcomes Uti-
izing Revascularization and Aggressive Drug Evaluation)
rial that compared optimal medical therapy with and
ithout PCI for patients with stable coronary disease,
ompliance rates with medical therapy in the medically
reated cohort at 5 years of follow-up were 94% for aspirin,
3% for statins and 86% for beta-blockers, respectively (35).
However, the CRUSADE (Can Rapid Risk Stratification
f Unstable Angina Patients Suppress Adverse Outcomes
ith Early Implementation of the American College of
ardiology/American Heart Association Guidelines) regis-
ry found only 46% of patients were compliant with beta-
lockers alone, and only 21% were compliant with beta-
lockers, aspirin, and lipid-lowering therapy together
36,37). Thus, the rates reported in the COURAGE trial
re unlikely to be reproducible in real-world settings. In
ddition, medical noncompliance has been shown to be
ssociated with higher mortality in late follow-up (36,38).
ence, it is likely that the case-management nature of the
ollow-up in the COURAGE trial resulted in considerably
etter outcomes for medically treated patients than would
ccur in typical settings.
riteria for Evaluating Quality of RCTs and OS
n view of the possible threats to validity in both RCTs and
S, the following are some questions to ask when evaluat-
ng the quality of a study:
uality of the database. Does the database contain all of the
haracteristics/variables known to be necessary to obtain valid
onclusions? Are the variables collected and measured in a
ell-defined clinically meaningful manner? If it is an observa-
ional database, does it contain the patient risk factors known
o be significant predictors of the outcomes being tracked and
tudied? Is unmeasured confounding/selection bias a signifi-
ant threat to the findings of the study?
atients. Are the patients in the study the right patients to
est the study hypothesis? If the study is an observational
atabase, is there enough information about patients to
ake appropriate exclusions? If the study is an RCT, are the
xclusion and inclusion criteria broad enough to inform
road-based treatment decisions made on the basis of the
tudy findings?
O
f
t
s
i
S
e
c
“
a
t
t
b
h
A
d
t
n
s
F
t
c
c
C
T
i
o
a
g
r
o
t
o
R
S
m
v
1
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
2
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 1 , N O . 3 , 2 0 0 8
J U N E 2 0 0 8 : 2 1 1 – 7
Hannan
Randomized Trials Versus Observational Studies
216utcomes. Are the outcomes used in the study meaning-
ul ones? Are there combined end points that mix impor-
ant outcomes (e.g., mortality) with relatively unimportant or
ubjective outcomes. Are important outcomes included
ndividually?
ize and generality of the database. Is the database large
nough to yield the statistical power needed to identify
linically meaningful differences in the important outcomes?
Clinically meaningful differences” should be defined in
dvance of the study. Is the sample of patients generalizable
o other settings? Is there just a single site or very few sites
hat may not be representative of outcomes at other sites
ecause of special circumstances such as physician quality,
ospital quality or exceptional resources?
nalysis strategy. If the study is based on an observational
atabase, are differences in patient risk factors between
reatments being controlled for adequately using a combi-
ation of multivariable adjustment and a method for testing
election bias such as propensity analysis?
ollow-up. Is the follow-up period long enough to capture
he outcomes being evaluated? Is the follow-up process
omplete and does it mirror real-world practice? Is the study
ompromised by loss to follow-up?
onclusions
he aforementioned criteria (and perhaps others I have
nadvertently omitted) are the most important determinants
f whether a database and the methodology for analyzing it
re adequate for obtaining valid conclusions, or whether a
iven database/analysis plan is superior to another one,
egardless of whether the database is an RCT or an
bservational database. The design and ultimate conduct of
he study is the principal criterion to consider, not the type
f study per se (19,20).
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